Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : receives Advanced and Overseas R&D finding

09/13/2021 | 11:22pm EDT

View printer-friendly version

Brisbane, Australia, 14 September 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased to announce that it has received approval from AusIndustry for its application for an Advanced and Overseas Finding in respect to expenditure associated with its COVID-19 clinical studies.

The finding covers financial years 2021, 2022 and 2023 and means that eligible overseas research and development expenditure in ResApp's COVID-19 clinical studies, in additional to Australian expenditure, will be subject to a 43.5% cash rebate under the Australian Federal Government's R&D Tax Incentive Program. The company now estimates that it will receive an R&D rebate of approximately $820,000 for the financial year ended 30 June 2021.

In the US, ResApp is recruiting participants in a pilot study to collect data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone (ref ASX announcement 11 March 2021). Participants from this first study are also recruited into a second study which will collect additional cough sounds and data on disease progression to develop algorithms to remotely monitor patients with COVID-19 (ref ASX announcement 9 August 2021).

ResApp has also engaged Triomics, an Indian clinical trial company, to recruit patients in India (ref ASX announcement 9 August 2021). Recruitment in India is expected to begin shortly.

CEO and Managing Director, Dr Tony Keating commented: 'Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs. We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.'


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.


ResApp Health Limited published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 03:21:00 UTC.

© Publicnow 2021
10/10RESAPP HEALTH : ReAapp Health Seeks US FDA Nod for Apnea Assessment Mobile App
10/10RESAPP HEALTH : announces FDA 510(k) submission for SleepCheckRx
10/10Resapp Announces FDA 510(K) Submission for Sleepcheckrx
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
More news
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -5,10 M -5,10 M
Net cash 2021 6,40 M 4,82 M 4,82 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 57,6 M 43,3 M 43,4 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SNAP INC.51.09%121 588
ANGI INC.-5.49%6 328
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-47.86%4 696
KAKAO GAMES CORP.54.35%4 579